Results Healthcare   |   Results International

Insights

We add value by understanding our sectors inside out, and release regular industry research and reports

Results Healthcare has advised Sino Biopharmaceutical Limited on its acquisition of Softhale

By Kevin Bottomley, Issac Jacob 23 Mar 2021

Sino Biopharmaceutical Limited has acquired Softhale

Results Healthcare is delighted to have advised Sino Biopharmaceutical Limited, the leading innovative research and R&D-driven pharmaceutical group in China, on its acquisition of Softhale NV, a privately owned Belgian company focused on the development of products for the treatment of respiratory diseases.

Softhale’s next-generation Soft Mist Inhalation (“SMI”) device is based upon differentiated technology and allows for more efficient drug deposition into the lungs. The acquisition will enhance Sino Biopharmaceutical’s transformation from generics to an innovative player by acquiring and fully controlling its own respiratory research and development capability. It will also accelerate Sino Biopharmaceutical’s internationalisation strategy by establishing a local hub in Europe as well as developing products with significant global market potential.

>>>> read the press release here

This transaction is further testament to Results Healthcare’s expertise in the pharmaceutical and medical devices sectors and highlights the team’s strong relationships in the life sciences.

 

Our expertise in the Life Sciences

 

Kevin Bottomley

Partner

Contact Kevin

Issac Jacob

Director

Contact Issac

Insights

Regular Public Healthcare Sector Analysis, News, Blogs & White Papers

View our insights     SUBSCRIBE

Connect with us

Follow Results Healthcare on Twitter Follow Results Healthcare on LinkedIn

Your Nearest Office